Skip to Main Content
Table 1—

Baseline characteristics for all patients receiving treatment

Insulin detemirNPH insulin
n 301 146 
Age (years) 38.9 ± 13.3 41.8 ± 14.2 
Sex   
 M 162 (53.8) 74 (50.7) 
 F 139 (46.2) 72 (49.3) 
Weight (kg) 71.5 ± 11.9 71.2 ± 11.5 
BMI (kg/m224.5 ± 3.2 24.6 ± 3.4 
Diabetes duration (years) 17.1 ± 9.9 17.4 ± 11.0 
FPG (mmol/l) 11.6 ± 5.21 11.6 ± 5.27 
HbA1c (%) 8.18 ± 1.14 8.11 ± 1.12 
Total daily insulin dose (units)*   
 Basal 27.4 ± 12.5 25.2 ± 13.7 
 Bolus 30.9 ± 15.5 29.6 ± 15.8 
Insulin detemirNPH insulin
n 301 146 
Age (years) 38.9 ± 13.3 41.8 ± 14.2 
Sex   
 M 162 (53.8) 74 (50.7) 
 F 139 (46.2) 72 (49.3) 
Weight (kg) 71.5 ± 11.9 71.2 ± 11.5 
BMI (kg/m224.5 ± 3.2 24.6 ± 3.4 
Diabetes duration (years) 17.1 ± 9.9 17.4 ± 11.0 
FPG (mmol/l) 11.6 ± 5.21 11.6 ± 5.27 
HbA1c (%) 8.18 ± 1.14 8.11 ± 1.12 
Total daily insulin dose (units)*   
 Basal 27.4 ± 12.5 25.2 ± 13.7 
 Bolus 30.9 ± 15.5 29.6 ± 15.8 

Data are means ± SD or n (%).

*

Does not include patients using premix insulin at study start: insulin detemir group, 27 IU/U (n = 1); NPH insulin group, 40 IU/U (n = 1).

Close Modal

or Create an Account

Close Modal
Close Modal